BACKGROUND. Prostate-specific antigen (PSA) is secreted exclusively by prostatic epithelial cells, and its serum concentration is increased in men with prostatic disease, including cancer. We evaluated its usefulness in the detection and staging of prostate cancer. METHODS. We measured serum PSA concentrations in 1653 healthy men 50 or more years old. Those with PSA values greater than or equal to 4.0 micrograms per liter then underwent rectal examination and prostatic ultrasonography. Ultrasound-directed prostatic needle biopsies were performed in the men with abnormal findings on rectal examination, ultrasonography, or both. The results were compared with those in 300 consecutively studied men 50 or more years old who underwent ultrasound-directed biopsy because of symptoms or abnormal findings on rectal examination. RESULTS. Serum PSA levels ranged from 4.0 to 9.9 micrograms per liter in 6.5 percent of the 1653 men (107). Nineteen of the 85 men in this group (22 percent) who had prostatic biopsies had prostate cancer. Serum PSA levels were 10.0 micrograms per liter or higher in 1.8 percent of the 1653 men (30). Eighteen of the 27 men in this group (67 percent) who had prostatic biopsies had cancer. If rectal examination alone had been used to screen the men who had biopsies, 12 of the 37 cancers (32 percent) would have been missed. If ultrasonography alone had been used to screen these men, 16 of the 37 cancers (43 percent) would have been missed. Serum PSA measurement had the lowest error rate of the tests, and PSA measurement plus rectal examination had the lowest error rate of the two-test combinations. CONCLUSIONS. The combination of measurement of the serum PSA concentration and rectal examination, with ultrasonography performed in patients with abnormal findings, provides a better method of detecting prostate cancer than rectal examination alone.
Source Information
Department of Surgery, Washington University School of Medicine, St. Louis, MO.
This article has been cited by other articles:
Welch, H. G., Albertsen, P. C.
(2009). Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. JNCI J Natl Cancer Inst
101: 1325-1329
[Abstract][Full Text]
Troyer, D. A., Lucia, M. S., de Bruine, A. P., Mendez-Meza, R., Baldewijns, M. M., Dunscomb, N., Van Engeland, M., McAskill, T., Bierau, K., Louwagie, J., Bigley, J. W.
(2009). Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies. Cancer Epidemiol. Biomarkers Prev.
18: 2717-2722
[Abstract][Full Text]
Ilic, D., Green, S.
(2009). Prostate specific antigen for detecting early prostate cancer. BMJ
339: b3572-b3572
[Full Text]
Nelson, W. G., De Marzo, A. M., Yegnasubramanian, S.
(2009). Epigenetic Alterations in Human Prostate Cancers. Endocrinology
150: 3991-4002
[Abstract][Full Text]
Hillier, S. M., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., Joyal, J. L., Babich, J. W.
(2009). Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Res.
69: 6932-6940
[Abstract][Full Text]
Zhu, L., Koistinen, H., Landegren, U., Stenman, U.-H.
(2009). Proximity Ligation Measurement of the Complex between Prostate Specific Antigen and {alpha}1-Protease Inhibitor. Clin. Chem.
55: 1665-1671
[Abstract][Full Text]
Arneth, B. M.
(2009). Clinical Significance of Measuring Prostate-Specific Antigen. Lab Med
40: 487-491
[Abstract][Full Text]
Boyle, P., Brawley, O. W.
(2009). Prostate Cancer: Current Evidence Weighs Against Population Screening. CA Cancer J Clin
59: 220-224
[Full Text]
Brawley, O. W., Ankerst, D. P., Thompson, I. M.
(2009). Screening for Prostate Cancer. CA Cancer J Clin
59: 264-273
[Abstract][Full Text]
Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L.J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Berenguer, A., Maattanen, L., Bangma, C. H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., Blijenberg, B. G., Moss, S. M., de Koning, H. J., Auvinen, A., the ERSPC Investigators,
(2009). Screening and Prostate-Cancer Mortality in a Randomized European Study. NEJM
360: 1320-1328
[Abstract][Full Text]
Dry, S.
(2009). Who Owns Diagnostic Tissue Blocks?. Lab Med
40: 69-73
[Full Text]
Vickers, A. J., Lilja, H.
(2009). Cutpoints in Clinical Chemistry: Time for Fundamental Reassessment. Clin. Chem.
55: 15-17
[Full Text]
Bellera, C. A., Hanley, J. A., Joseph, L., Albertsen, P. C.
(2008). Detecting Trends in Noisy Data Series: Application to Biomarker Series. Am J Epidemiol
167: 1130-1139
[Abstract][Full Text]
Loeb, S., Catalona, W. J.
(2008). What to Do with an Abnormal PSA Test. The Oncologist
13: 299-305
[Abstract][Full Text]
Laxman, B., Morris, D. S., Yu, J., Siddiqui, J., Cao, J., Mehra, R., Lonigro, R. J., Tsodikov, A., Wei, J. T., Tomlins, S. A., Chinnaiyan, A. M.
(2008). A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer. Cancer Res.
68: 645-649
[Abstract][Full Text]
Zhang, K., Aruva, M. R., Shanthly, N., Cardi, C. A., Rattan, S., Patel, C., Kim, C., McCue, P. A., Wickstrom, E., Thakur, M. L.
(2008). PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. JNM
49: 112-121
[Abstract][Full Text]
McLerran, D., Grizzle, W. E., Feng, Z., Thompson, I. M., Bigbee, W. L., Cazares, L. H., Chan, D. W., Dahlgren, J., Diaz, J., Kagan, J., Lin, D. W., Malik, G., Oelschlager, D., Partin, A., Randolph, T. W., Sokoll, L., Srivastava, S., Srivastava, S., Thornquist, M., Troyer, D., Wright, G. L., Zhang, Z., Zhu, L., Semmes, O. J.
(2008). SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin. Chem.
54: 53-60
[Abstract][Full Text]
Jewett, M. A.S., Klotz, L. H., for the University of Toronto Uro-Oncology Program,
(2007). Advances in the medical management of benign prostatic hyperplasia. CMAJ
176: 1850-1851
[Full Text]
Thompson, I. M., Ankerst, D. P.
(2007). Prostate-specific antigen in the early detection of prostate cancer. CMAJ
176: 1853-1858
[Abstract][Full Text]
Safarinejad, M. R.
(2006). Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol
17: 1166-1171
[Abstract][Full Text]
Taylor, L. S., Rubens, D. J., Porter, B. C., Wu, Z., Baggs, R. B., di Sant'Agnese, P. A., Nadasdy, G., Pasternack, D., Messing, E. M., Nigwekar, P., Parker, K. J.
(2005). Prostate Cancer: Three-dimensional Sonoelastography for in Vitro Detection. Radiology
237: 981-985
[Abstract][Full Text]
Talcott, J. A.
(2005). Rebalancing Ratios and Improving Impressions: Later Thoughts From the Prostate Cancer Prevention Trial Investigators. JCO
23: 7388-7390
[Full Text]
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., Kantoff, P. W., Rubin, M. A., Wei, J. T., Ghosh, D., Chinnaiyan, A. M.
(2005). Autoantibody Signatures in Prostate Cancer. NEJM
353: 1224-1235
[Abstract][Full Text]
Bernstein, J. L., Godbold, J. H., Raptis, G., Watson, M. A., Levinson, B., Aaronson, S. A., Fleming, T. P.
(2005). Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer. Clin. Cancer Res.
11: 6528-6535
[Abstract][Full Text]
Welch, H. G., Schwartz, L. M., Woloshin, S.
(2005). Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal. JNCI J Natl Cancer Inst
97: 1132-1137
[Abstract][Full Text]
Paul, B., Dhir, R., Landsittel, D., Hitchens, M. R., Getzenberg, R. H.
(2005). Detection of Prostate Cancer with a Blood-Based Assay for Early Prostate Cancer Antigen. Cancer Res.
65: 4097-4100
[Abstract][Full Text]
Bradley, S. V., Oravecz-Wilson, K. I., Bougeard, G., Mizukami, I., Li, L., Munaco, A. J., Sreekumar, A., Corradetti, M. N., Chinnaiyan, A. M., Sanda, M. G., Ross, T. S.
(2005). Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. Cancer Res.
65: 4126-4133
[Abstract][Full Text]
Freedland, S. J., Isaacs, W. B., Mangold, L. A., Yiu, S. K., Grubb, K. A., Partin, A. W., Epstein, J. I., Walsh, P. C., Platz, E. A.
(2005). Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years. Clin. Cancer Res.
11: 2883-2888
[Abstract][Full Text]
Grossman, H. B., Messing, E., Soloway, M., Tomera, K., Katz, G., Berger, Y., Shen, Y.
(2005). Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay. JAMA
293: 810-816
[Abstract][Full Text]
Beyersdorff, D., Winkel, A., Hamm, B., Lenk, S., Loening, S. A., Taupitz, M.
(2005). MR Imaging-guided Prostate Biopsy with a Closed MR Unit at 1.5 T: Initial Results. Radiology
234: 576-581
[Abstract][Full Text]
Johansson, J.-E., Andren, O., Andersson, S.-O., Dickman, P. W., Holmberg, L., Magnuson, A., Adami, H.-O.
(2004). Natural History of Early, Localized Prostate Cancer. JAMA
291: 2713-2719
[Abstract][Full Text]
Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y.-J., Sweeney, C., Whiteside, T. L., Schlom, J., Wilding, G., Weiner, L. M.
(2004). Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. JCO
22: 2122-2132
[Abstract][Full Text]
Mikolajczyk, S. D., Catalona, W. J., Evans, C. L., Linton, H. J., Millar, L. S., Marker, K. M., Katir, D., Amirkhan, A., Rittenhouse, H. G.
(2004). Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer. Clin. Chem.
50: 1017-1025
[Abstract][Full Text]
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., Coltman, C. A. Jr.
(2004). Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level <=4.0 ng per Milliliter. NEJM
350: 2239-2246
[Abstract][Full Text]
Taylor, P. R., Parnes, H. L., Lippman, S. M.
(2004). Science Peels the Onion of Selenium Effects on Prostate Carcinogenesis. JNCI J Natl Cancer Inst
96: 645-647
[Full Text]
Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., Zahurak, M., Piantadosi, S., Walsh, P. C., Bova, G. S., De Marzo, A. M., Isaacs, W. B., Nelson, W. G.
(2004). Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer. Cancer Res.
64: 1975-1986
[Abstract][Full Text]
Law, M.
(2004). Screening without evidence of efficacy. BMJ
328: 301-302
[Full Text]
Mohler, J. L., Gregory, C. W., Ford, O. H. III, Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., French, F. S.
(2004). The Androgen Axis in Recurrent Prostate Cancer. Clin. Cancer Res.
10: 440-448
[Abstract][Full Text]
Thompson, I., Leach, R. J., Pollock, B. H., Naylor, S. L.
(2003). Prostate Cancer and Prostate-Specific Antigen: The More We Know, the Less We Understand. JNCI J Natl Cancer Inst
95: 1027-1028
[Full Text]
Aksoy, Y., Oral, A., Aksoy, H., Demirel, A., Akcay, F.
(2003). PSA Density and PSA Transition Zone Density in the Diagnosis of Prostate Cancer in PSA Gray Zone Cases. Annals of Clinical & Laboratory Science
33: 320-323
[Abstract][Full Text]
Wesseling, S., Stephan, C., Semjonow, A., Lein, M., Brux, B., Sinha, P., Loening, S. A., Jung, K.
(2003). Determination of Non-{alpha}1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy. Clin. Chem.
49: 887-894
[Abstract][Full Text]
Khan, M. A., Partin, A. W.
(2003). Management of High-Risk Populations with Locally Advanced Prostate Cancer. The Oncologist
8: 259-269
[Abstract][Full Text]
Eastham, J. A., Riedel, E., Scardino, P. T., Shike, M., Fleisher, M., Schatzkin, A., Lanza, E., Latkany, L., Begg, C. B.
(2003). Variation of Serum Prostate-Specific Antigen Levels: An Evaluation of Year-to-Year Fluctuations. JAMA
289: 2695-2700
[Abstract][Full Text]
Oottamasathien, S., Crawford, E. D.
(2003). Should Routine Screening for Prostate-Specific Antigen Be Recommended?. Arch Intern Med
163: 661-663
[Full Text]
Linton, H. J., Marks, L. S., Millar, L. S., Knott, C. L., Rittenhouse, H. G., Mikolajczyk, S. D.
(2003). Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease. Clin. Chem.
49: 253-259
[Abstract][Full Text]
Balk, S. P., Ko, Y.-J., Bubley, G. J.
(2003). Biology of Prostate-Specific Antigen. JCO
21: 383-391
[Abstract][Full Text]
Ferrando, A. A., Sheffield-Moore, M., Paddon-Jones, D., Wolfe, R. R., Urban, R. J.
(2003). Differential Anabolic Effects of Testosterone and Amino Acid Feeding in Older Men. J. Clin. Endocrinol. Metab.
88: 358-362
[Abstract][Full Text]
Zhu, L., Leinonen, J., Zhang, W.-M., Finne, P., Stenman, U.-H.
(2003). Dual-Label Immunoassay for Simultaneous Measurement of Prostate-specific Antigen (PSA)-{alpha}1-Antichymotrypsin Complex Together with Free or Total PSA. Clin. Chem.
49: 97-103
[Abstract][Full Text]
Isono, T., Tanaka, T., Kageyama, S., Yoshiki, T.
(2002). Structural Diversity of Cancer-related and Non-Cancer-related Prostate-specific Antigen. Clin. Chem.
48: 2187-2194
[Abstract][Full Text]
Leinonen, J., Wu, P., Stenman, U.-H.
(2002). Epitope Mapping of Antibodies against Prostate-specific Antigen with Use of Peptide Libraries. Clin. Chem.
48: 2208-2216
[Abstract][Full Text]
Jain, S, Bhojwani, A G, Mellon, J K
(2002). Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad. Med. J.
78: 646-650
[Abstract][Full Text]
Beyersdorff, D., Taupitz, M., Winkelmann, B., Fischer, T., Lenk, S., Loening, S. A., Hamm, B.
(2002). Patients with a History of Elevated Prostate-Specific Antigen Levels and Negative Transrectal US-guided Quadrant or Sextant Biopsy Results: Value of MR Imaging. Radiology
224: 701-706
[Abstract][Full Text]
Bunker, C. H., Patrick, A. L., Konety, B. R., Dhir, R., Brufsky, A. M., Vivas, C. A., Becich, M. J., Trump, D. L., Kuller, L. H.
(2002). High Prevalence of Screening-detected Prostate Cancer among Afro-Caribbeans: The Tobago Prostate Cancer Survey. Cancer Epidemiol. Biomarkers Prev.
11: 726-729
[Abstract][Full Text]
Rawstron, A. C., Green, M. J., Kuzmicki, A., Kennedy, B., Fenton, J. A. L., Evans, P. A. S., O'Connor, S. J. M., Richards, S. J., Morgan, G. J., Jack, A. S., Hillmen, P.
(2002). Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood
100: 635-639
[Abstract][Full Text]
Djavan, B., Remzi, M., Zlotta, A., Seitz, C., Snow, P., Marberger, M.
(2002). Novel Artificial Neural Network for Early Detection of Prostate Cancer. JCO
20: 921-929
[Abstract][Full Text]
Serdar, M. A., Oguz, O., Olgun, A., Seckin, B., Ilgan, S., Hasimi, A., Salih, M., Peker, F., Kutluay, T.
(2002). Diagnostic Approach to Prostate Cancer using Total Prostate Specific Antigen-Based Parameters Together. Annals of Clinical & Laboratory Science
32: 22-30
[Abstract][Full Text]
Shenk, J. L., Fisher, C. J., Chen, S.-Y., Zhou, X.-F., Tillman, K., Shemshedini, L.
(2001). p53 Represses Androgen-induced Transactivation of Prostate-specific Antigen by Disrupting hAR Amino- to Carboxyl-terminal Interaction. J. Biol. Chem.
276: 38472-38479
[Abstract][Full Text]
Mikolajczyk, S. D., Marker, K. M., Millar, L. S., Kumar, A., Saedi, M. S., Payne, J. K., Evans, C. L., Gasior, C. L., Linton, H. J., Carpenter, P., Rittenhouse, H. G.
(2001). A Truncated Precursor Form of Prostate-specific Antigen Is a More Specific Serum Marker of Prostate Cancer. Cancer Res.
61: 6958-6963
[Abstract][Full Text]
Yousef, G. M., Diamandis, E. P.
(2001). The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease. Endocr. Rev.
22: 184-204
[Abstract][Full Text]
Ganz, P. A., Litwin, M. S.
(2001). Prostate Cancer: The Price of Early Detection. JCO
19: 1587-1588
[Full Text]
Thornbury, J. R., Ornstein, D. K., Choyke, P. L., Langlotz, C. P., Weinreb, J. C.
(2001). Prostate Cancer: What Is the Future Role for Imaging?. Am. J. Roentgenol.
176: 17-22
[Full Text]
Stephan, C., Jung, K., Lein, M., Sinha, P., Schnorr, D., Loening, S. A.
(2000). Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev.
9: 1133-1147
[Abstract][Full Text]
Finne, P., Auvinen, A., Koistinen, H., Zhang, W.-M., Määttänen, L., Rannikko, S., Tammela, T., Seppälä, M., Hakama, M., Stenman, U.-H.
(2000). Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen. J. Clin. Endocrinol. Metab.
85: 2744-2747
[Abstract][Full Text]
Uchida, K., Takeshima, H., Akaza, H., Ono, Y.
(2000). Screening for Prostate Cancer Using Prostate-specific Antigen Alone as a First-line Checkup Parameter: Results of the Health Checkup System. Jpn J Clin Oncol
30: 95-100
[Abstract][Full Text]
Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Rittenhouse, H. G., Marks, L. S., Song, W., Wheeler, T. M., Slawin, K. M.
(2000). A Precursor Form of Prostate-specific Antigen Is More Highly Elevated in Prostate Cancer Compared with Benign Transition Zone Prostate Tissue. Cancer Res.
60: 756-759
[Abstract][Full Text]
Prakash, S., Robbins, P. W.
(2000). Glycotyping of prostate specific antigen. Glycobiology
10: 173-176
[Abstract][Full Text]
Negri, C., Tosi, F., Dorizzi, R., Fortunato, A., Spiazzi, G. G., Muggeo, M., Castello, R., Moghetti, P.
(2000). Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women. J. Clin. Endocrinol. Metab.
85: 81-84
[Abstract][Full Text]
Tanaka, T., Isono, T., Yoshiki, T., Yuasa, T., Okada, Y.
(2000). A Novel Form of Prostate-specific Antigen Transcript Produced by Alternative Splicing. Cancer Res.
60: 56-59
[Abstract][Full Text]
Jung, K., Elgeti, U., Lein, M., Brux, B., Sinha, P., Rudolph, B., Hauptmann, S., Schnorr, D., Loening, S. A.
(2000). Ratio of Free or Complexed Prostate-specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer?. Clin. Chem.
46: 55-62
[Abstract][Full Text]
Stege, R., Grande, M., Carlström, K., Tribukait, B., Pousette, A.
(2000). Prognostic Significance of Tissue Prostate-specific Antigen in Endocrine-treated Prostate Carcinomas. Clin. Cancer Res.
6: 160-165
[Abstract][Full Text]
Hoogendam, A., Buntinx, F., de Vet, H. C.
(1999). The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract
16: 621-626
[Abstract][Full Text]
Sutkowski, D. M., Goode, R. L., Baniel, J., Teater, C., Cohen, P., McNulty, A. M., Hsiung, H. M., Becker, G. W., Neubauer, B. L.
(1999). Growth Regulation of Prostatic Stromal Cells by Prostate-Specific Antigen. JNCI J Natl Cancer Inst
91: 1663-1669
[Abstract][Full Text]
Jhaveri, F. M., Klein, E. A., Kupelian, P. A., Zippe, C., Levin, H. S.
(1999). Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration. JCO
17: 3167-3172
[Abstract][Full Text]
Virtanen, A., Gomari, M., Kranse, R.
(1999). Estimation of Prostate Cancer Probability by Logistic Regression: Free and Total Prostate-specific Antigen, Digital Rectal Examination, and Heredity Are Significant Variables. Clin. Chem.
45: 987-994
[Abstract][Full Text]
Stenman, U.-H.
(1999). New Ultrasensitive Assays Facilitate Studies on the Role of Human Glandular Kallikrein (hK2) as a Marker for Prostatic Disease. Clin. Chem.
45: 753-754
[Full Text]
Zhang, W.-M., Finne, P., Leinonen, J., Vesalainen, S., Nordling, S., Stenman, U.-H.
(1999). Measurement of the Complex between Prostate-specific Antigen and {alpha}1-Protease Inhibitor in Serum. Clin. Chem.
45: 814-821
[Abstract][Full Text]
Scher, H. I.
(1999). Management of Prostate Cancer After Prostatectomy: Treating the Patient, Not the PSA. JAMA
281: 1642-1645
[Full Text]
Michel, S., Deleage, G., Charrier, J.-P., Passagot, J., Battail-Poirot, N., Sibai, G., Jolivet, M., Jolivet-Reynaud, C.
(1999). Anti-Free Prostate-specific Antigen Monoclonal Antibody Epitopes Defined by Mimotopes and Molecular Modeling. Clin. Chem.
45: 638-650
[Abstract][Full Text]
Nelson, P. S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L., Wang, K.
(1999). Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl. Acad. Sci. USA
96: 3114-3119
[Abstract][Full Text]
Mohan, R. R., Challa, A., Gupta, S., Bostwick, D. G., Ahmad, N., Agarwal, R., Marengo, S. R., Amini, S. B., Paras, F., MacLennan, G. T., Resnick, M. I., Mukhtar, H.
(1999). Overexpression of Ornithine Decarboxylase in Prostate Cancer and Prostatic Fluid in Humans. Clin. Cancer Res.
5: 143-147
[Abstract][Full Text]
Saedi, M. S., Hill, T. M., Kuus-Reichel, K., Kumar, A., Payne, J., Mikolajczyk, S. D., Wolfert, R. L., Rittenhouse, H. G.
(1998). The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin. Chem.
44: 2115-2119
[Abstract][Full Text]
Stern, S., Altkorn, D., Levinson, W.
(1998). Detection of Prostate and Colon Cancer. JAMA
280: 117-118
[Full Text]
Allard, W. J., Zhou, Z., Yeung, K. K.
(1998). Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin. Chem.
44: 1216-1223
[Abstract][Full Text]
Takayama, T. K., Fujikawa, K., Davie, E. W.
(1997). Characterization of the Precursor of Prostate-specific Antigen. ACTIVATION BY TRYPSIN AND BY HUMAN GLANDULAR KALLIKREIN. J. Biol. Chem.
272: 21582-21588
[Abstract][Full Text]
Cleutjens, K. B. J .M., van der Korput, H. A. G. M., Ehren-van Eekelen, C. C., Sikes, R. A., Fasciana, C., Chung, L. W., Trapman, J.
(1997). A 6-kb Promoter Fragment Mimics in Transgenic Mice the Prostate-Specific and Androgen-Regulated Expression of the Endogenous Prostate-Specific Antigen Gene in Humans. Mol. Endocrinol.
11: 1256-1265
[Abstract][Full Text]
Catalona, W. J., Smith, D. S., Ornstein, D. K.
(1997). Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination: Enhancement of Specificity With Free PSA Measurements. JAMA
277: 1452-1455
[Abstract]
Cleutjens, K. B. J. M., van der Korput, H. A. G. M., van Eekelen, C. C. E. M., van Rooij, H. C. J., Faber, P. W., Trapman, J.
(1997). An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter. Mol. Endocrinol.
11: 148-161
[Abstract][Full Text]
Collins, M. M., Barry, M. J.
(1996). Controversies in Prostate Cancer Screening: Analogies to the Early Lung Cancer Screening Debate. JAMA
276: 1976-1979
[Abstract]
Morgentaler, A., Bruning, C. O. III, DeWolf, W. C.
(1996). Occult Prostate Cancer in Men With Low Serum Testosterone Levels. JAMA
276: 1904-1906
[Abstract]
Smith, D. S., Catalona, W. J., Herschman, J. D.
(1996). Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen. JAMA
276: 1309-1315
[Abstract]
Cleutjens, K. B. J. M., van Eekelen, C. C. E. M., van der Korput, H. A. G. M., Brinkmann, A. O., Trapman, J.
(1996). Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter. J. Biol. Chem.
271: 6379-6388
[Abstract][Full Text]
Previous
